EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Zelira Therapeutics's enterprise value is A$7.11 Mil.
Zelira Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.28 Mil. Therefore, Zelira Therapeutics's EV-to-Revenue for today is 25.47.
The historical rank and industry rank for Zelira Therapeutics's EV-to-Revenue or its related term are showing as below:
ASX:ZLD'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.61 Med: 29.77 Max: 121.16
Current: 25.47
During the past 13 years, the highest EV-to-Revenue of Zelira Therapeutics was 121.16. The lowest was 3.61. And the median was 29.77.
ASX:ZLD's EV-to-Revenue is ranked worse than 70.16% of 1039
companies
in the Biotechnology industry
Industry Median: 8.18
vs ASX:ZLD: 25.47
The historical data trend for Zelira Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zelira Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Zelira Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zelira Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Zelira Therapeutics's EV-to-Revenue falls into.
Zelira Therapeutics's current Enterprise Value is A$7.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zelira Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zelira Therapeutics's share price for today is A$0.48.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zelira Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Zelira Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Zelira Therapeutics (ASX:ZLD) Business Description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:ZLD has been successfully added to your 